Lin Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lin Lin has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Liang Ma
Critical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, MD 20892, USA
4 shared publications Fan Guo
Department of Nephrology, Institute of Kidney Diseases, West China Hospital of Sichuan University, Chengdu, China
2 shared publications- Fan Guo
Department of Nephrology, Institute of Kidney Diseases West China Hospital of Sichuan University Chengdu China
2 shared publications Ping Fu
Department of Nephrology, Institute of Kidney Diseases, West China Hospital of Sichuan University, and National Key Laboratory of Kidney Diseases, Chengdu, China
2 shared publications- Ping Fu
West China Hospital, Sichuan University
2 shared publications Ting Xiang
Department of Nephrology, Institute of Kidney Diseases, West China Hospital of Sichuan University, Chengdu, China
2 shared publications
Latest Publications
- Open Access
- 14 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 9782
Tubular ACSM3 controls fatty acid metabolism and safeguards against acute kidney injury in male mice
Kidney tubular epithelial cells exceptionally exhibit high energy demands and preferentially metabolize long-chain fatty acids via fatty acid oxidation (FAO), where the impairment of FAO represents a hallmark of acute kidney injury (AKI). However, the role of medium-chain fatty acid metabolism in kidney injury remains unexplored. Here, we identify that tubular acyl-CoA synthetase medium-chain family member 3 (ACSM3), the key enzyme responsible for medium-chain fatty acid activation, is significantly down-regulated in damaged kidneys of distinct AKI male mouse models and acute tubular necrosis patients. Unexpectedly, tubule-specific ACSM3 deletion improves renal dysfunction, pathological damage, and metabolic disturbances in AKI male mice. Mechanistically, tubular ACSM3 deficiency preserves free fatty acid pool and reduces medium-chain fatty acids utilization, where these unused medium-chain fatty acids as ligands can activate peroxisome proliferator-activated receptor alpha (PPARα) and further upregulate PPARα-associated fatty acid metabolic genes to repair injured kidneys. Notably, dietary supplementation of medium-chain fatty acids confers protective effects against AKI in male mice. Our findings highlight tubular ACSM3 as a potential therapeutic target to control renal fatty acid metabolism and provide preclinical evidence that medium-chain fatty acid supplementation safeguards against AKI.
- 14 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 9782
Open AccessTubular ACSM3 controls fatty acid metabolism and safeguards against acute kidney injury in male mice
Kidney tubular epithelial cells exceptionally exhibit high energy demands and preferentially metabolize long-chain fatty acids via fatty acid oxidation (FAO), where the impairment of FAO represents a hallmark of acute kidney injury (AKI). However, the role of medium-chain fatty acid metabolism in kidney injury remains unexplored. Here, we identify that tubular acyl-CoA synthetase medium-chain family member 3 (ACSM3), the key enzyme responsible for medium-chain fatty acid activation, is significantly down-regulated in damaged kidneys of distinct AKI male mouse models and acute tubular necrosis patients. Unexpectedly, tubule-specific ACSM3 deletion improves renal dysfunction, pathological damage, and metabolic disturbances in AKI male mice. Mechanistically, tubular ACSM3 deficiency preserves free fatty acid pool and reduces medium-chain fatty acids utilization, where these unused medium-chain fatty acids as ligands can activate peroxisome proliferator-activated receptor alpha (PPARα) and further upregulate PPARα-associated fatty acid metabolic genes to repair injured kidneys. Notably, dietary supplementation of medium-chain fatty acids confers protective effects against AKI in male mice. Our findings highlight tubular ACSM3 as a potential therapeutic target to control renal fatty acid metabolism and provide preclinical evidence that medium-chain fatty acid supplementation safeguards against AKI.
- Open Access
- 23 May 2026
- Published by Wiley in Aging Cell
- Vol. 25 (6) , e70546
Tubular Omega‐3 Fatty Acid Receptor FFAR4 Deficiency Aggravated Renal Aging and Chronic Kidney Disease
Aging leads to renal function decline and increases the risk of chronic kidney disease (CKD). Omega‐3 polyunsaturated fatty acids (PUFAs) are essential fatty acids for humans, exerting their functions via free fatty acid receptor 4 (FFAR4). Clinical studies indicate that omega‐3 PUFAs supplementation shows benefits for the elderly population and CKD patients, but these results remain controversial. Herein, we found that omega‐3 PUFAs alleviated renal fibrosis and tubular senescence in aged mice, adenine diet‐induced CKD mice, and unilateral ureteral obstruction (UUO) mice. Meanwhile, omega‐3 fatty acid receptor FFAR4 expression in tubular epithelial cells (TECs) were down‐regulated in the old population and CKD patients, positively correlated with renal dysfunction. Systemic or TEC‐specific knockout of FFAR4 aggravated renal aging and CKD in mice. Mechanically, FFAR4 agonism increases the production of endogenous PPARγ activator 15‐deoxy‐∆12,14‐Prostaglandin J2 (15d‐PGJ2), and improves PPARγ‐dependent tubular epithelial cell senescence, which was indicated by anti‐aging marker Klotho expression, senescence‐associated β‐galactosidase (SA‐β‐gal) activity, and profibrotic factor TGF‐β1 secretion. The study demonstrated a novel role of FFAR4 from senescent TECs on fibroblast activation via paracrine effects and highlighted the therapeutic effects of omega‐3 PUFAs with their receptor FFAR4 as an attractive drug target against renal aging and CKD.
- 23 May 2026
- Published by Wiley in Aging Cell
- Vol. 25 (6) , e70546
Open AccessTubular Omega‐3 Fatty Acid Receptor FFAR4 Deficiency Aggravated Renal Aging and Chronic Kidney Disease
Aging leads to renal function decline and increases the risk of chronic kidney disease (CKD). Omega‐3 polyunsaturated fatty acids (PUFAs) are essential fatty acids for humans, exerting their functions via free fatty acid receptor 4 (FFAR4). Clinical studies indicate that omega‐3 PUFAs supplementation shows benefits for the elderly population and CKD patients, but these results remain controversial. Herein, we found that omega‐3 PUFAs alleviated renal fibrosis and tubular senescence in aged mice, adenine diet‐induced CKD mice, and unilateral ureteral obstruction (UUO) mice. Meanwhile, omega‐3 fatty acid receptor FFAR4 expression in tubular epithelial cells (TECs) were down‐regulated in the old population and CKD patients, positively correlated with renal dysfunction. Systemic or TEC‐specific knockout of FFAR4 aggravated renal aging and CKD in mice. Mechanically, FFAR4 agonism increases the production of endogenous PPARγ activator 15‐deoxy‐∆12,14‐Prostaglandin J2 (15d‐PGJ2), and improves PPARγ‐dependent tubular epithelial cell senescence, which was indicated by anti‐aging marker Klotho expression, senescence‐associated β‐galactosidase (SA‐β‐gal) activity, and profibrotic factor TGF‐β1 secretion. The study demonstrated a novel role of FFAR4 from senescent TECs on fibroblast activation via paracrine effects and highlighted the therapeutic effects of omega‐3 PUFAs with their receptor FFAR4 as an attractive drug target against renal aging and CKD.
- 23 July 2024
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 45 (12) , 2598-2610
Chromodomain Y‐like (CDYL) inhibition ameliorates acute kidney injury in mice by regulating tubular pyroptosis
Acute kidney injury (AKI) is a common disease, but lacking effective drug treatments. Chromodomain Y‐like (CDYL) is a kind of chromodomain protein that has been implicated in transcription regulation of autosomal dominant polycystic kidney disease. Benzo[d]oxazol-2(3H)-one derivative (compound D03) is the first potent and selective small-molecule inhibitor of CDYL (KD = 0.5 μM). In this study, we investigated the expression of CDYL in three different models of cisplatin (Cis)-, lipopolysaccharide (LPS)- and ischemia/reperfusion injury (IRI)-induced AKI mice. By conducting RNA sequencing and difference analysis of kidney samples, we found that tubular CDYL was abnormally and highly expressed in injured kidneys of AKI patients and mice. Overexpression of CDYL in cisplatin-induced AKI mice aggravated tubular injury and pyroptosis via regulating fatty acid binding protein 4 (FABP4)-mediated reactive oxygen species production. Treatment of cisplatin-induced AKI mice with compound D03 (2.5 mg·kg−1·d−1, i.p.) effectively attenuated the kidney dysfunction, pathological damages and tubular pyroptosis without side effects on liver or kidney function and other tissue injuries. Collectively, this study has, for the first time, explored a novel aspect of CDYL for tubular epithelial cell pyroptosis in kidney injury, and confirmed that inhibition of CDYL might be a promising therapeutic strategy against AKI.
- 23 July 2024
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 45 (12) , 2598-2610
Chromodomain Y‐like (CDYL) inhibition ameliorates acute kidney injury in mice by regulating tubular pyroptosis
Acute kidney injury (AKI) is a common disease, but lacking effective drug treatments. Chromodomain Y‐like (CDYL) is a kind of chromodomain protein that has been implicated in transcription regulation of autosomal dominant polycystic kidney disease. Benzo[d]oxazol-2(3H)-one derivative (compound D03) is the first potent and selective small-molecule inhibitor of CDYL (KD = 0.5 μM). In this study, we investigated the expression of CDYL in three different models of cisplatin (Cis)-, lipopolysaccharide (LPS)- and ischemia/reperfusion injury (IRI)-induced AKI mice. By conducting RNA sequencing and difference analysis of kidney samples, we found that tubular CDYL was abnormally and highly expressed in injured kidneys of AKI patients and mice. Overexpression of CDYL in cisplatin-induced AKI mice aggravated tubular injury and pyroptosis via regulating fatty acid binding protein 4 (FABP4)-mediated reactive oxygen species production. Treatment of cisplatin-induced AKI mice with compound D03 (2.5 mg·kg−1·d−1, i.p.) effectively attenuated the kidney dysfunction, pathological damages and tubular pyroptosis without side effects on liver or kidney function and other tissue injuries. Collectively, this study has, for the first time, explored a novel aspect of CDYL for tubular epithelial cell pyroptosis in kidney injury, and confirmed that inhibition of CDYL might be a promising therapeutic strategy against AKI.